Chaperone-dependent stabilization and degradation of p53 mutants

Oncogene

Volumn 27, Issue 24, 2008, Pages 3371-3383

  Muller, P ^a,b   Hrstka, R ^a   Coomber, D ^b   Lane, D P ^b   Vojtesek, B ^a  

^a MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^b INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

Author keywords

Chaperones; CHIP; Degradation; p53 mutant; Stabilization

Indexed keywords

CHAPERONE; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; NUTLIN 3; PROTEIN P53;

ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FOLDING; PROTEIN INTERACTION; PROTEIN STABILITY; UBIQUITINATION;

ANIMALS; BENZOQUINONES; CELLS, CULTURED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBROBLASTS; HSC70 HEAT-SHOCK PROTEINS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; LACTAMS, MACROCYCLIC; MICE; MICE, KNOCKOUT; MUTATION; NEOPLASMS; PROTEIN CONFORMATION; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

EID: 44149124776     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1211010     Document Type: Article

References (41)

1. Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F et al. (2005). Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 280: 26729-26734.
2. Ballinger CA, Connell P, Wu Y, Hu Z, Thompson LJ, Yin LY et al. (1999). Identification of CHIP, a novel tetratricopeptide repeat-containing protein that interacts with heat shock proteins and negatively regulates chaperone functions. Mol Cell Biol 19: 4535-4545.
3. Barak Y, Juven T, Haffner R, Oren M. (1993). mdm2 expression is induced by wild type p53 activity. EMBO J 12: 461-468.
4. Barrette RW, Urbonas J, Silbart LK. (2006). Quantifying specific antibody concentrations by enzyme-linked immunosorbent assay using slope correction. Clin Vaccine Immunol 13: 802-805.
5. Bartek J, Bartkova J, Lukas J, Staskova Z, Vojtesek B, Lane DP. (1993). Immunohistochemical analysis of the p53 oncoprotein on paraffin sections using a series of novel monoclonal antibodies. J Pathol 169: 27-34.
6. Blagosklonny MV. (1997). Loss of function and p53 protein stabilization. Oncogene 15: 1889-1893.
7. Blagosklonny MV. (2004). Flavopiridol, an inhibitor of transcription: implications, problems and solutions. Cell Cycle 3: 1537-1542.
8. Blagosklonny MV, Toretsky J, Neckers L. (1995). Geldanamycin selectively destabilizes and conformationally alters mutated p53. Oncogene 11: 933-939.
9. Blagosklonny MV, Trostel S, Kayastha G, Demidenko ZN, Vassilev LT, Romanova LY et al. (2005). Depletion of mutant p53 and cytotoxicity of histone deacetylase inhibitors. Cancer Res 65: 7386-7392.
10. Bullock AN, Fersht AR. (2001). Rescuing the function of mutant p53. Nat Rev Cancer 1: 68-76.
11. Chen J, Marechal V, Levine AJ. (1993). Mapping of the p53 and mdm-2 interaction domains. Mol Cell Biol 13: 4107-4114.
12. Dornan D, Wertz I, Shimizu H, Arnott D, Frantz GD, Dowd P et al. (2004). The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature 429: 86-92.
13. Esser C, Alberti S, Hohfeld J. (2004). Cooperation of molecular chaperones with the ubiquitin/proteasome system. Biochim Biophys Acta 1695: 171-188.
14. Esser C, Scheffner M, Hohfeld J. (2005). The chaperone-associated ubiquitin ligase CHIP is able to target p53 for proteasomal degradation. J Biol Chem 280: 27443-27448.
15. Gannon JV, Greaves R, Iggo R, Lane DP. (1990). Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 9: 1595-1602.
16. George P, Bali P, Annavarapu S, Scuto A, Fiskus W, Guo F et al. (2005). Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 105: 1768-1776.
17. Grossman SR, Deato ME, Brignone C, Chan HM, Kung AL, Tagami H et al. (2003). Polyubiquitination of p53 by a ubiquitin ligase activity of p300. Science 300: 342-344.
18. Hinds PW, Finlay CA, Frey AB, Levine AJ. (1987). Immunological evidence for the association of p53 with a heat shock protein, hsc70, in p53-plus-ras-transformed cell lines. Mol Cell Biol 7: 2863-2869.
19. Jackson EL, Olive KP, Tuveson DA, Bronson R, Crowley D, Brown M et al. (2005). The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res 65: 10280-10288.
20. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC et al. (2003). A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425: 407-410.
21. King FW, Wawrzynow A, Hohfeld J, Zylicz M. (2001). Co-chaperones Bag-1, Hop and Hsp40 regulate Hsc70 and Hsp90 interactions with wild-type or mutant p53. EMBO J 20: 6297-6305.
22. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM et al. (2004). Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119: 861-872.
23. Leng RP, Lin Y, Ma W, Wu H, Lemmers B, Chung S et al. (2003). Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell 112: 779-791.
24. Milner J. (1997). Structures and functions of the tumor suppressor p53. Pathol Biol (Paris) 45: 797-803.
25. Nagata Y, Anan T, Yoshida T, Mizukami T, Taya Y, Fujiwara T et al. (1999). The stabilization mechanism of mutant-type p53 by impaired ubiquitination: the loss of wild-type p53 function and the hsp90 association. Oncogene 18: 6037-6049.
26. Nenutil R, Smardova J, Pavlova S, Hanzelkova Z, Muller P, Fabian P et al. (2005). Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry. J Pathol 207: 251-259.
27. Nimmanapalli R, Fuino L, Bali P, Gasparetto M, Glozak M, Tao J et al. (2003). Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res 63: 5126-5135.
28. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT et al. (2004). Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119: 847-860.
29. O'Shea CC, Soria C, Bagus B, McCormick F. (2005). Heat shock phenocopies E1B-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy. Cancer Cell 8: 61-74.
30. Peng Y, Chen L, Li C, Lu W, Agrawal S, Chen J. (2001a). Stabilization of the MDM2 oncoprotein by mutant p53. J Biol Chem 276: 6874-6878.
31. Peng Y, Chen L, Li C, Lu W, Chen J. (2001b). Inhibition of MDM2 by hsp90 contributes to mutant p53 stabilization. J Biol Chem 276: 40583-40590.
32. Selkirk JK, Merrick BA, Stackhouse BL, He C. (1994). Multiple p53 protein isoforms and formation of oligomeric complexes with heat shock proteins Hsp70 and Hsp90 in the human mammary tumor, T47D, cell line. Appl Theor Electrophor 4: 11-18.
33. Soussi T, Lozano G. (2005). p53 mutation heterogeneity in cancer. Biochem Biophys Res Commun 331: 834-842.
34. Wang PL, Sait F, Winter G. (2001). The 'wildtype' conformation of p53: epitope mapping using hybrid proteins. Oncogene 20: 2318-2324.
35. Wang Y, Wang SY, Zhang XH, Zhao M, Hou CM, Xu YJ et al. (2007). FK228 inhibits Hsp90 chaperone function in K562 cells via hyperacetylation of Hsp70. Biochem Biophys Res Commun 356: 998-1003.
36. Vojtesek B, Bartek J, Midgley CA, Lane DP. (1992). An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods 151: 237-244.
37. Vojtesek B, Fisher CJ, Barnes DM, Lane DP. (1993). Comparison between p53 staining in tissue sections and p53 proteins levels measured by an ELISA technique. Br J Cancer 67: 1254-1258.
38. Workman P. (2004). Altered states: selectively drugging the Hsp90 cancer chaperone. Trends Mol Med 10: 47-51.
39. Wu X, Bayle JH, Olson D, Levine AJ. (1993). The p53-mdm-2 autoregulatory feedback loop. Genes Dev 7: 1126-1132.
40. Zhang Y, Wang JS, Chen LL, Cheng XK, Heng FY, Wu NH et al. (2004). Repression of hsp90beta gene by p53 in UV irradiation-induced apoptosis of Jurkat cells. J Biol Chem 279: 42545-42551.
41. Zylicz M, King FW, Wawrzynow A. (2001). Hsp70 interactions with the p53 tumour suppressor protein. EMBO J 20: 4634-4638.